Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $17.10

Posted by on Jun 12th, 2023

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating)’s share price gapped up prior to trading on Monday . The stock had previously closed at $17.10, but opened at $17.54. Calliditas Therapeutics AB (publ) shares last traded at $17.79, with a volume of 1,700 shares.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, February 28th. They issued a “neutral” rating on the stock. Citigroup boosted their target price on shares of Calliditas Therapeutics AB (publ) from $76.00 to $79.00 and gave the company a “buy” rating in a report on Friday, February 24th.

Calliditas Therapeutics AB (publ) Trading Down 0.6 %

The firm’s fifty day moving average is $22.13 and its 200-day moving average is $20.33. The company has a quick ratio of 3.89, a current ratio of 3.93 and a debt-to-equity ratio of 1.27.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

Institutional investors have recently made changes to their positions in the stock. HBK Sorce Advisory LLC raised its holdings in shares of Calliditas Therapeutics AB (publ) by 100.0% during the fourth quarter. HBK Sorce Advisory LLC now owns 90,000 shares of the company’s stock valued at $104,000 after purchasing an additional 45,000 shares during the period. Optiver Holding B.V. raised its holdings in shares of Calliditas Therapeutics AB (publ) by 1,304.3% during the third quarter. Optiver Holding B.V. now owns 12,625 shares of the company’s stock valued at $191,000 after purchasing an additional 11,726 shares during the period. Deutsche Bank AG raised its holdings in shares of Calliditas Therapeutics AB (publ) by 26.5% during the first quarter. Deutsche Bank AG now owns 90,509 shares of the company’s stock valued at $2,170,000 after purchasing an additional 18,978 shares during the period. Jane Street Group LLC acquired a new position in shares of Calliditas Therapeutics AB (publ) during the first quarter valued at about $221,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Calliditas Therapeutics AB (publ) by 1,270.2% during the third quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after purchasing an additional 3,112 shares during the period. Institutional investors and hedge funds own 3.13% of the company’s stock.

About Calliditas Therapeutics AB (publ)

(Get Rating)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.

Read More

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.